Navigation Links
Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)
Date:1/22/2008

testosterone levels, minimal excursions outside of the normal range, and an extremely high percentage of patients maintaining a eugonadal (normal) testosterone range. NEBIDO met its primary endpoints, a responder analysis based on average testosterone concentrations during the steady state dosing interval and an outlier analysis based on the maximum testosterone concentrations during the steady state dosing interval. As with the original dosing regimen, treatment with NEBIDO was well tolerated with this new dosing regimen.

"As we have previously stated, we have been evaluating dosing regimens that we believe optimize the replacement of testosterone in men with hypogonadism. I am extremely pleased that the dosing regimen evaluated in this study accomplishes this objective," stated Glenn L. Cooper, M.D., chairman and chief executive officer of Indevus. "The results of our trial demonstrate a rapid achievement of steady-state testosterone levels, the maintenance of levels within the eugonadal range, and reductions in excursions above the normal range. Steady state testosterone pharmacokinetics were achieved within just weeks under the new regimen, whereas the 1000 mg regimen, while successfully achieving all primary objectives, reached steady state pharmacokinetics after several months of treatment."

Dr. Cooper continued, "We intend to ask for approval of this new 750 mg regimen, rather than the 1000 mg regimen, as we believe this new regimen distinguishes itself by providing physicians with the optimal long-term dosing solution for treating their male patients with hypogonadism. Importantly, we are extremely pleased with the feedback we recently received from the FDA that the PDUFA target action date was likely to remain unchanged."

Study Design

The most recent Phase III pharmacokinetic trial was an open-label (unblinded) study that evaluated treatment with an initial 750 mg of NEBIDO given via intramuscular injection, followed 4-weeks lat
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Indevus Announces Submission of New Drug Application
3. Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Spherix Reports Second Quarter Earnings
6. Tapestry Reports Second Quarter 2007 Results
7. Callisto Reports on Second-Quarter 2007 Milestones
8. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
9. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
10. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
11. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... Calif. , July 28, 2015  Nevro ... device company that is providing innovative evidence-based solutions ... the publication of the SENZA-RCT results in the ... Journal of the American Society of Anesthesiologists. ... ground-breaking study that was the first to directly ...
(Date:7/28/2015)...  PD-Rx Pharmaceuticals, Inc., a publicly held corporation, ... with Dobson Technologies, a fully-integrated outsourced IT provider, ... PD-Rx is an Application Service Provider ... Using Dobson Technologies, IaaS solution will allow PD-Rx ... regulatory compliance, and reduce operating expenses.  "The most ...
(Date:7/28/2015)... BIRMINGHAM, Ala. , July 28, 2015   ... butler for surgeons , has just hired John ... and Business Development. John has over 30 years of ... executive roles. Mr. O,Neil,s executive healthcare experience coupled with ... an active surgeon allows Vincari to address the challenges ...
Breaking Medicine Technology:Nevro Announces Publication of SENZA-RCT Results in Anesthesiology 2PD-Rx Partners With Dobson Technologies 2John O'Neil Joins Vincari as Executive Vice President of Strategy and Business Development 2
(Date:7/29/2015)... Estates, IL (PRWEB) , ... July 29, 2015 , ... ... both benefit from two new products on Mercola.com: a vertical “garden tower” and enhanced ... which can be squeezed into small corners on a porch, balcony, or rooftop – ...
(Date:7/29/2015)... ... July 29, 2015 , ... Elizabeth Callahan, M.D., ... to be chosen by the manufacturer to offer and perform Kybella™ ... way to treat and eliminate double chin fat,” Dr. Callahan explained. “Previously this ...
(Date:7/29/2015)... Thomasville, North Carolina (PRWEB) , ... July 29, 2015 , ... ... hammer and nails in an assisted nursing facility, but that’s exactly what was happening ... Frequent visitors to the facility are 3- and 4-year-olds from Kids Only , ...
(Date:7/28/2015)... ... July 29, 2015 , ... Meet ... and other A-Listers, has evolved into a world class millionaires club, according to ... to match successful and attractive people seeking real, meaningful and mutually beneficial relationships ...
(Date:7/28/2015)... ... 29, 2015 , ... City Sports, a specialty sports retailer and a premiere ... Hanaka as CEO. , Hanaka, who has served on the Board of Directors for ... the Highland Consumer Fund has had previous tenures as Chairman and CEO of Golfsmith ...
Breaking Medicine News(10 mins):Health News:Mercola.com Introduces NEW Garden Tower and Enhanced Mineral Solution for Healthy Plants 2Health News:SkinSmart Dermatology is First in Sarasota to Offer Kybella Treatments to Reduce Double Chin Fat 2Health News:SkinSmart Dermatology is First in Sarasota to Offer Kybella Treatments to Reduce Double Chin Fat 3Health News:North Carolina Retirement Community Re-Launches Intergenerational Programming with Onsite Daycare Center 2Health News:North Carolina Retirement Community Re-Launches Intergenerational Programming with Onsite Daycare Center 3Health News:North Carolina Retirement Community Re-Launches Intergenerational Programming with Onsite Daycare Center 4Health News:Meet a Millionaire Announces It’s Not a Sugar Daddy Site, It’s a True Millionaires Club 2Health News:City Sports Names Marty Hanaka CEO 2
... 3 HIV/AIDS drugs, Viraday that needs to be taken just ... three anti-HIV drugs efavirenz 600 mg, tenofovir 300 mg and ... alone effectively treats a HIV infected person, eliminates the need ... it is less burdensome and it can be taken along ...
... drug misoprostol, normally used to treat ulcers, was found ... death of women in developing countries, according// to a ... of Missouri, India's Jawaharlal Nehru Medical College, and the ... in the Oct. 8 issue of Lancet, found misoprostol ...
... at the Launceston General Hospital have developed a revolutionary ... of the LGH Dementia Research Centre George Razay merely ... type of dementia. ,Over 5000 Tasmanians are affected by ... by 2050. ,20 patients, equal number ...
... the intensive care unit previously occupied by ... the odds of acquiring such bacteria.// ... death in hospitals: methicillin-resistant Staphylococcus aureus (MRSA) ... information in the article. Researchers previously found ...
... Poor services are provided by doctors and dentists according ... trust which runs Barrowa€?s Furness General Hospital is rated ... has roundly criticised the NHS services in Cumbria. ... more wide-ranging and tougher than the old hotel-style star ...
... cell is a reservoir of proteins and performs the role of ... none other than the cell nucleus//, which houses the DNA, and ... particular protein is to be manufactured, the command is reproduced verbatim ... like substance, and is carried via pores in the cell nucleus ...
Cached Medicine News:Health News:Ulcer Drug Could Save Lives of Women in Developing Countries 2Health News:Transmission of Antibiotic-Resistant Bacteria Linked to Previous ICU Room Occupants 2Health News:The Living Cell – Manufacturing, Protecting and Thrivin 2
Upper arm protection...
Lap pad used to protect pelvic regions...
Light and comfortable thyroid protection. The softest, most comfortable throid collar made. No neck irritating binding....
The front of this apron is tapered for maximum adjustability as needed. We can include a specially designed half-apron to be worn under the full apron for double protection in the abdomen/pelvic cav...
Medicine Products: